Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307171 | 0.79 | GAA (0.50) | ALDH1A1MAPK1GAA | |
| SCHEMBL6307060 | 0.78 | ALDH1A1 (0.64) | ALDH1A1MAPK1TSHRMEN1KMT2A | |
| SCHEMBL6307905 | 0.76 | CYBB (0.58) | ALDH1A1MAPK1TSHRMEN1KMT2A | |
| SCHEMBL6314302 | 0.74 | HSP90AA1 (0.41) | ALDH1A1MAPK1MEN1KMT2AMAPT | |
| SCHEMBL6310015 | 0.72 | ALDH1A1 (0.50) | ALDH1A1MAPK1TSHRMEN1KMT2A | |
| SCHEMBL6310022 | 0.72 | ALDH1A1 (0.50) | ALDH1A1MAPK1TSHRMEN1KMT2A | |
| SCHEMBL6314269 | 0.69 | L3MBTL1 (0.44) | ALDH1A1MAPK1TSHRKDM4EMAPT | |
| SCHEMBL1876523 | 0.66 | MEN1 (0.87) | ALDH1A1MAPK1TSHRMEN1KMT2A | |
| SCHEMBL2633644 | 0.65 | MEN1 (0.54) | ALDH1A1TSHRMEN1KMT2AKDM4E | |
| SCHEMBL8556657 | 0.65 | MEN1 (0.51) | ALDH1A1TSHRMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919339-B2 | ABCA-1 elevating compounds | CV THEAPEUTICS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1341773-A2 | SUBSTITUTED 1,3,5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20020128266-A1 | ABCA-1 elevating compounds | CV THERAPEUTICS, INC. | 2002-09-12 | — | — | US | disclosed |
| WO-2002046172-A2 | SUBSTITUTED 1, 3, 5-TRIAZINES AND PYRIMIDINES AS ABCA-1 ELEVATING COMPOUNDS AGAINST CORONARY ARTERY DISEASE OR ATHEROSCLEROSIS | CV THERAPEUTICS, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128266-A1 | ABCA-1 elevating compounds | ABCD3, ABCE1, ABCB4 | ALDH1A1 399/4885MAPK1 2892/4885TSHR 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.